https://wikimd.org/index.php?action=history&feed=atom&title=VM-902AVM-902A - Revision history2026-04-25T18:47:09ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=VM-902A&diff=6023884&oldid=prevPrab: CSV import2024-12-02T05:12:16Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Infobox drug<br />
| name = VM-902A<br />
| image = <!-- Image of the chemical structure --><br />
| width = 250px<br />
| alt = <!-- Alt text for the image --><br />
| caption = Chemical structure of VM-902A<br />
| legal_status = Investigational<br />
| routes_of_administration = Oral<br />
| bioavailability = <!-- Bioavailability information --><br />
| protein_bound = <!-- Protein binding information --><br />
| metabolism = <!-- Metabolism information --><br />
| elimination_half-life = <!-- Half-life information --><br />
| excretion = <!-- Excretion information --><br />
| CAS_number = <!-- CAS number --><br />
| ATC_prefix = <!-- ATC code --><br />
| ATC_suffix = <!-- ATC code --><br />
| PubChem = <!-- PubChem ID --><br />
| DrugBank = <!-- DrugBank ID --><br />
| ChemSpiderID = <!-- ChemSpider ID --><br />
| UNII = <!-- UNII code --><br />
| KEGG = <!-- KEGG ID --><br />
| ChEBI = <!-- ChEBI ID --><br />
| ChEMBL = <!-- ChEMBL ID --><br />
}}<br />
<br />
'''VM-902A''' is an investigational drug currently under development for the treatment of [[neurodegenerative diseases]], particularly [[Alzheimer's disease]]. It is a small molecule that has shown promise in preclinical studies for its potential neuroprotective and cognitive-enhancing effects.<br />
<br />
==Mechanism of Action==<br />
VM-902A is believed to exert its effects through multiple mechanisms. It is thought to modulate [[neurotransmitter]] systems, including the [[cholinergic system]], which is crucial for memory and learning. Additionally, VM-902A may have antioxidant properties that help reduce oxidative stress, a contributing factor in neurodegeneration.<br />
<br />
==Pharmacokinetics==<br />
The pharmacokinetic profile of VM-902A is still under investigation. Preliminary studies suggest that it is orally bioavailable and has a moderate half-life, allowing for convenient dosing schedules. Further studies are needed to fully elucidate its absorption, distribution, metabolism, and excretion (ADME) characteristics.<br />
<br />
==Clinical Trials==<br />
As of the latest updates, VM-902A is undergoing Phase II clinical trials. These trials aim to assess its efficacy and safety in patients with mild to moderate Alzheimer's disease. Initial results have been promising, showing improvements in cognitive function and daily living activities compared to placebo.<br />
<br />
==Potential Side Effects==<br />
The safety profile of VM-902A is still being established. Common side effects observed in early trials include mild gastrointestinal disturbances and headache. No serious adverse events have been reported thus far, but ongoing studies will provide more comprehensive safety data.<br />
<br />
==Research and Development==<br />
VM-902A is being developed by a consortium of academic and industry partners. The development process involves extensive collaboration to optimize its therapeutic potential and ensure regulatory compliance. The drug's development is supported by funding from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.<br />
<br />
==Also see==<br />
* [[Alzheimer's disease]]<br />
* [[Neurodegenerative diseases]]<br />
* [[Cholinergic system]]<br />
* [[Oxidative stress]]<br />
<br />
{{Drug development}}<br />
{{Neuropharmacology}}<br />
<br />
[[Category:Investigational drugs]]<br />
[[Category:Neuropharmacology]]<br />
[[Category:Alzheimer's disease treatment]]</div>Prab